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Introduction
Acute lymphoblastic leukemia (ALL) accounts for less than
20% of adult acute leukemias. The t(4;11)(q21;q23) is a fre-
quent abnormality in this disease.1-3 This translocation fuses
the ALL1 (MLL, HRX, Hrtx1)4-8 gene to the AF4 gene. This
alteration identifies a subset of ALL with aggressive clinical
features and poor outcome.9,10 In addition, the ALL1(MLL)/AF4
fusion is associated with a pro-B immunophenotype.11 This
fusion gene is detectable in the vast majority of pro-B ALL
cases in infancy12 and only in 30-40% of adults.10 Due to this
association with age, in infancy the pro-B immunophenotype
and t(4;11) have often been considered as equivalent prognos-
tic factors.
By contrast, in adults there is no such strong association and
the lack, until 1990, of a centralized diagnostic procedure in
large cooperative studies, such as the GIMEMA 0288 trial,13
may have underscored the adverse prognosis conferred by
these genetic alterations.
Recently, among a series of adults with pro-B ALL receiving
the conventional chemotherapy regimen of the GIMEMA 0496
trial, we demonstrated that the ALL1(MLL)/AF4 genotypic fea-
tures was the only parameter conferring an adverse clinical
outcome to this specific subset of ALL patients.10 For these rea-
sons, in the subsequent GIMEMA LAL 2000 study, the
ALL1(MLL)/AF4 ALL positive patients would be managed
more intensively with one course of HD Ara-C/mitoxantrone
and HSCT as consolidation treatments. 
Therefore, herein, we report the clinical outcome of
ALL1(MLL)/AF4 positive ALL patients entered into the two
consecutive GIMEMA trials looking for possible differences
between the two adopted strategies. 
Design and Methods
Patients
Twenty-one adult (18-60 years) patients with ALL1(MLL)/AF4
positive ALL were enrolled into the GIMEMA LAL 2000 study
between January 2000 and September 2004, while 25 patients
entered into the GIMEMA 0496 study active between October
1996 and December 1999. The diagnosis of ALL was based on
standard morphological and cytochemical evaluation14 and on
immunophenotypic criteria. 
All patients gave informed consent for both treatment and
diagnostic procedures. The two studies were approved by our
institutional review board.
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The clinical outcome of 21 adults with ALL1(MLL)/AF4 posi-
tive acute lymphoblastic leukemia enrolled in the GIMEMA
LAL 2000 trial and of 25 patients entered into the previous
0496 study is reported. LAL 2000 included more intensive
consolidation and transplants. Complete remission rates were
90% and 88% in the LAL 2000 and 0496 trials, respectively.
Fifteen patients were transplanted (5 autologous, 10 allogene-
ic). At 36 months, overall and disease free survivals were
32.9%, 31.8%, 28% and 27.3%, in LAL 2000 and 0496 trials,
respectively. Relapses remained the main reason of failure
occurring in 10 and 16 of  the 19 and 22 responding patients.
In the LAL 2000 study, 4 relapses were observed before trans-
plant. Thus, ALL1(MLL)/AF4 abnormality characterized a
subset of patients with adverse prognosis in which the over-
all strategy adopted in the LAL 2000 study, rather than trans-
plants per se, failed to improve the patient clinical outcome.
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Molecular analysis
Total RNA was extracted from cells cryopreserved in
guanidium isothiocyanate according to the method of
Chomczynsky and Sacchi.15 The quality of RNA was
assessed on an ethidium bromide-stained 1% agarose gel
containing 2.2 M formaldehyde. 
In vitro reverse transcription of 1 mg total RNA to cDNA
was performed using the commercial kit Gene Amp RNA
PCR kit (Applied Biosystems, Foster City, CA) according to
the manufacture’s instructions. RT-PCR amplification of the
ALL1(MLL)/AF4 fusion transcript and of the normal ALL1
gene were performed according to the methods previously
described.16
Treatment 
The GIMEMA 0496 and LAL 2000 studies included an
identical induction therapy with 4 drugs (prednisone [PDN],
vincristine [VCR], daunorubicin [DNR], and asparaginase
[ASP]) with high-dose DNR (270 mg/m2).10 A seven day pred-
nisone pre-treatment was added in the GIMEMA LAL 2000
study. The two protocols differed in their post-induction
treatments. The GIMEMA 0496 included two consolidation
courses with high-dose Ara-C (2gr/m2 every 12 hours as 3-
hour infusion on days 1 and 2) and etoposide11 followed by
three years of maintenance treatment, whereas in the
GIMEMA LAL 2000 patients received one course of high-
dose Ara-C (two daily doses at 3 gr/m2, days 1, 2, 3 and 4)
and mitoxantrone (10 mg/m2, days 3, 4 and 5) followed by
an allogeneic or autologous HSCT according to the availabil-
ity of an HLA-compatible donor of hematopoietic stem cells.
Response criteria
All patients starting induction therapy have been consid-
ered for statistical analysis. Therapeutic responses were eval-
uated at the end of induction treatment in all cases.
Complete Remission (CR) was defined as the normalization
of peripheral blood count and less than 5% blasts in the bone
marrow (BM) with normal cellularity. Relapse was defined
as the reappearance of leukemic cells in the bone marrow (>
5% blasts) and/or reappearance of clinical evidence of the
disease.
Statistical analysis
Differences in the distribution of factors in subgroups
were analyzed by χ2 or Fisher’s exact test, and by the
Kruskal-Wallis test, as appropriate. Overall Survival (OS) was
defined as the time from diagnosis to death or date of the last
follow-up; Disease Free Survival (DFS) was calculated from
the time of achieving CR to relapse, death or date of last fol-
low-up. The probabilities of OS and DFS were estimated
using the Kaplan-Meier method; differences between distri-
bution were evaluated by means of the Log-Rank test; confi-
dence intervals (C.I. 95%) were estimated using the Simon
and Lee method. The hypothesis of proportionality was test-
ed using Schoenfeld’s partial residuals. All tests were two-
sided; P≤0.05 was considered statistically significant. All
analyses where performed using the SAS software (SAS
Institute, Cary, NC). 
Results and Discussion
In the present study, we describe the clinical course of 46
ALL1(MLL)/AF4 positive adult ALL patients consecutively
treated in two multicenter GIMEMA trials: this represents
the largest cohort of patients showing this rare genetic alter-
ation described in the literature. All patients had a pro-B ALL.
As reported in Table 1, there was no difference in the main
clinical and biological characteristics of the ALL1(MLL)/AF4
positive ALL patients. The karyotype was available in 38
cases (83%) and a t(4;11)(q21;q23) cytogenetic alteration was
detected in 31 cases. None of the cases showed a t(9;22)
and/or expressed the BCR/ABL fusion.
Table 2 summarizes the therapeutic response and clinical
outcome recorded in the two groups of patients. A hemato-
logic CR was achieved in 19 (90%) and in 22 (88%) of the 21
and 25 ALL patients treated according to the LAL 2000 and
0496 trials, respectively (P= n.s.). 
Among the 19 ALL cases in CR after the LAL 2000 induc-
tion, one patient received a conventional maintenance treat-
ment without transplant because of a severe cardiomyopa-
thy developed after induction-consolidation chemotherapy.
The patient relapsed 24 months after CR. Thirteen patients
received a transplant (5 autologous; 8 allogeneic) whereas 4
patients relapsed before transplant at a median time of 1.6
months (range 1.2-5.8) after CR; the remaining case was lost
to follow-up. Since our analyses were based on the intention
to treat, this latter patient was considered at risk for the time
he persisted in follow-up, thereafter he was censored at the
time he became lost to follow-up. Following a decision by
the attending physician, 2 additional patients of the
GIMEMA 0496 study were allotransplanted in first CR.
Therefore, altogether 15 patients were transplanted. Eight
cases received HSC from an HLA identical donor, one from
an unrelated and one from an aploidentical donor, whereas
the remaining 5 cases received autologous HSC. 
All transplanted patients received standard intensive con-
ditioning regimens that in the majority of cases consisted of
total body irradiation (TBI) and/or cyclophosphamide (CY),
and busulphan and CY. 
The probabilities of OS and of DFS are reported in Figure
1. The clinical outcome of the two patient groups were sim-
ilar; at 36 months, rates of OS and DFS were 32.9% (C.I.
95%: 26.6-40.7), 31.8% (C.I. 95%: 25.4-39.6), 28% (C.I.
95%: 23.5-33.4) and 27.3% (C.I. 95%: 22.6-32.9), respective-
ly, for patients who received the LAL 2000 and the 0496 pro-
tocols.
Disease relapses occurred in 10/19 (53%) patients in the
LAL 2000 protocol and in 16/22 (72%) patients who received
the GIMEMA 0496 treatment (P=n.s.). Source of HSCT did
not affect the relapse rate after transplant. In fact, among
patients treated with the LAL 2000 protocol, relapses
occurred in 2 of the 5 patients autografted and in 3 of the 10
patients who received allogeneic HSCT. In addition, in the
LAL 2000 protocol, the group of patients still in CR and those
who had relapsed showed a similar median time to trans-
plant, being 3.1 (1.8-6.1) and 2.8 (2-3.6) months, respectively. 
In order to try to define the impact of HSCT on the clini-
cal outcome of our patients, we first considered the occur-
rence of disease relapses and treatment failures (i.e. disease
relapses and deaths in CR for transplant related comorbidi-
ties) with respect to transplant. Overall, we observed a
relapse in 6/13 (excluding the 2 patients who died in CR) and
19/25 patients treated with HSCT or CHT alone, respective-
ly (P=0.066), whereas 8 of 15 and 19 of 25 patients who
received HSCT or CHT alone (P=0.175) failed the treatment.
Secondly, we constructed a Cox model to evaluate the prog-
nostic impact on DFS rates of the following variables: age
and WBC count at diagnosis, type of treatment and trans-
plant. This latter was considered as a time dependent covari-
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ate (i.e. the effect of transplant on each patient was analyzed
starting from the day of HSCT). Results of this analysis
showed that DFS rate was not significantly affected by any
of the variables considered. In particular, HSCT resulted in
an HR of 0.676 (95% CI: 0.222-2.059; P=0.4904). 
Although we observed a trend toward significance when
considering the differences in relapse rates between trans-
planted and non-transplanted patients, the intensified strate-
gy adopted in the LAL 2000 study, that included HSCT, did
not favorably impact on the clinical outcome of
ALL1(MLL)/AF4 positive ALL patients. 
The present findings are not powered enough to answer
the question on the efficacy of HSCT for the treatment of
this rare leukemic subtype because patients receiving HSCT
were too few to have a significant impact on the DFS.
However, it is worth noting that the lowest relapse rate was
observed after allogeneic HSCT (3/10). Therefore, this latter
should still be considered the treatment of choice for the
treatment of this genetically characterized adult ALL subtype
even if contrasting data have been reported. Results from the
MRC/ECOG 2993 study17 showed that, despite the use of
HSCT in first CR, the t(4;11) alteration still identified
patients with an adverse prognosis having low event free
survival and OS rates, due in part to relapses but also to
deaths in CR. By contrast, a superiority of allogeneic trans-
plant was demonstrated by the results of the prospective
multicenter LALA-94 study18 which showed that allogeneic
SCT was associated with a significantly improved DFS with
a plateau at 18 months. The advantage of transplant proce-
dures was also demonstrated by the German multicenter tri-
als GMALL 048919 in which, however, t(4;11) positive cases
were included in the larger pro-B immunophenotypic sub-
group, a leukemic subtype with a heterogeneous prognosis,
as previously reported.10
When considering the efficacy of HSCT in hematologic
malignancies, it is necessary to consider several variables.
One of the most important is the ability of pre-transplant
treatments to eradicate the malignant clones to the greatest
possible extent. This concept is based on several observa-
tions and has recently received further confirmation in Ph-
positive ALL. The use of tyrosine kinase inhibitors before
transplant, that results in an improved molecular remission
rate, was associated with a significant improvement in dis-
ease outcome after transplantation.20-22
Due to the limited number of our patients, we cannot
draw any definite conclusion. However, the failure of HSCT
to improve results in our ALL1(MLL)/AF4 positive ALL
patients might, therefore, be due to the weakness of the pre-
Intensive treatment for ALL1(MLL)/AF4 ALL
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Table 1. Clinico-biological characteristics of ALL-1(MLL)/AF4 positive
patients according to the treatment group.
GIMEMA LAL 0496 GIMEMA LAL 2000 P
N=25 N=21
Sex
males 14 8 0.2259
Females 11 13
Age
median 38.8 38.6 0.8694
range (14.9-59.4) (19.6-56.1)
WBC  at  diagnosis 
median 60.0 60.1 0.8522
range (2.2-663.0) (2.4-872.3)
HB at diagnosis 
median 9.0 8.9 0.8782
range (4.9-15.1) (3.0-12.7)
PLTs  at diagnosis
median 33.5 33.0 0.5520
range (1.0-153.0) (14.0-136.0)
BLAST % BM at diagnosis
median 95 93.0 0.2737
range (70.0-100.0) (75.0-99.0)
BLAST % PB at diagnosis 
median 91.5 87.0 0.1029
range (18.0-100.0) (32.0-99.0) 
Table 2. Therapeutic response and clinical outcome of ALL-
1(MLL)/AF4 positive  of all patients and according to the two different
protocols.
All patients GIMEMA GIMEMA 
(n=46) 0496 LAL 2000
(n=25) (n=21)
Response to induction therapy
CR 41 22 19
Resistant 5 3 2
Post-remission treatment
Allo-HSCT 10 2 8
Auto-HSCT 5 - 5
Maintenance 21 20 1
Clinical course
Pts. in CCR 13 6 7
Relapses 26 16 10 (4)*
Died in CR 2 0 2
*patients relapsed before HSCT; CCR: continuous complete remission; Allo-HSCT: allo-
geneic HSCT; auto-HSCT:  autologous HSCT.
Figure 1. Actuarial probability of OS (A) and DSF (B) according to
treatments  [LAL 2000 (–––––––––––) or LAL 0496 (–––––––––)].
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transplant strategy rather than to the effect of HSCT per se.
In fact: 1) the occurrence of several relapses before HSCT (4
of 10 ); 2) the fact that the more aggressive pre-transplant
regimen used in the LAL2000 protocol did not significantly
increase the molecular responses in comparison with the
GIMEMA-0496 protocol. In fact, at the end of
induction/consolidation treatments, the observed molecular
CR rates (i.e. absence of the specific ALL1(MLL)/AF4 ampli-
fication band in the presence of RNA integrity) were 66%
and 50% in the LAL 2000 and 0496 studies, respectively; 3)
the use of HSCT after even more aggressive regimens,
including cyclophosphamide, high-dose methotrexate and a
second course of high-dose AraC-mitoxantrone, resulted in a
better clinical outcome.17,18
It, therefore, appears that HSCT, to be effective, should be
preceded by a more effective pre-transplant treatment. 
The risk of an early relapse in ALL1(MLL)/AF4 positive
ALL patients should prompt the search for a potential donor
as soon as a diagnosis has been made. 
In conclusion, ALL1(MLL)/AF4 positive ALL remains an
attractive leukemic subtype in which to evaluate novel
strategies in order to improve chemotherapy activity and/or
reduce treatment toxicity.
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